Ken Griffin Bio N Tech Se Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio N Tech Se stock. As of the latest transaction made, Citadel Advisors LLC holds 207,300 shares of BNTX stock, worth $23.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
207,300
Previous 126,000
64.52%
Holding current value
$23.1 Million
Previous $11.6 Million
43.32%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding BNTX
# of Institutions
329Shares Held
38.8MCall Options Held
844KPut Options Held
1.4M-
Baillie Gifford & CO8.31MShares$926 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$504 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$486 Million2.05% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.93MShares$326 Million1.34% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$211 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $27.1B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...